Akero Therapeutics, Inc. (AKRO)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Akero Therapeutics, Inc. (AKRO) trades at $54.65 with AI Score 46/100 (Weak). Akero Therapeutics is a biotechnology company focused on developing treatments for nonalcoholic steatohepatitis (NASH). Market cap: $4.50B, Sector: Healthcare.
Last analyzed: Feb 3, 2026Akero Therapeutics, Inc. (AKRO) Healthcare & Pipeline Overview
Akero Therapeutics pioneers innovative therapies for NASH, leveraging its lead candidate efruxifermin (EFX) to restore metabolic balance and address a significant unmet need in cardio-metabolic diseases, offering a notable research candidate in the rapidly growing biotechnology sector.
Investment Thesis
Akero Therapeutics presents a notable research candidate due to its innovative approach to treating NASH with efruxifermin (EFX). EFX's unique mechanism of action, targeting the underlying metabolic dysfunction in NASH, differentiates it from other treatments. Positive clinical trial data from the BALANCED study could serve as a significant catalyst, driving stock appreciation. The company's focus on a high-growth market with limited treatment options further enhances its potential. With a market cap of $4.50 billion and a negative beta of -0.40, Akero offers a potentially attractive risk-adjusted return profile. Successful advancement of EFX through clinical trials and eventual commercialization could generate substantial revenue streams, making AKRO a promising investment for long-term growth.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $4.50B reflects investor confidence in Akero's potential in the NASH treatment market.
- P/E Ratio of -15.31 indicates the company is currently not profitable, typical for clinical-stage biotech companies investing heavily in R&D.
- Negative Beta of -0.40 suggests the stock price is less volatile than the overall market, offering some downside protection.
- Lead product candidate efruxifermin (EFX) targets a significant unmet need in NASH treatment, potentially capturing a large market share.
- Ongoing Phase 2a BALANCED study provides a near-term catalyst for potential positive data release, driving investor interest.
Competitors & Peers
Strengths
- Novel mechanism of action of efruxifermin (EFX).
- Strong intellectual property position.
- Experienced management team.
- Focus on a high-growth market with unmet medical need.
Weaknesses
- Reliance on a single lead product candidate (EFX).
- Limited commercialization experience.
- High cash burn rate typical of clinical-stage biotech companies.
- Negative P/E ratio indicating lack of profitability.
Catalysts
- Data readout from the Phase 2a BALANCED study evaluating EFX in NASH patients.
- Enrollment and progression of patients in ongoing clinical trials.
- Potential for strategic partnerships or collaborations with larger pharmaceutical companies.
Risks
- Clinical trial failures or delays.
- Regulatory setbacks or non-approval of EFX.
- Competition from other companies developing NASH treatments.
- High cash burn rate and need for additional financing.
Growth Opportunities
- Expansion into Adjacent Indications: Akero can leverage the mechanism of action of EFX to explore its potential in treating other cardio-metabolic diseases beyond NASH, such as type 2 diabetes and dyslipidemia. These adjacent markets represent significant growth opportunities, potentially expanding the addressable patient population and revenue streams. The market size for diabetes and dyslipidemia treatments is substantial, offering a long-term growth runway for Akero.
- Strategic Partnerships and Collaborations: Akero can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of EFX. Collaborations can provide access to additional resources, expertise, and distribution networks, enhancing Akero's ability to reach a broader patient base. These partnerships could also involve co-development agreements or licensing deals, generating upfront payments and milestone revenues.
- Advancement of Pipeline Candidates: Akero can invest in the development of additional pipeline candidates targeting different aspects of NASH or other metabolic diseases. A diversified pipeline reduces the company's reliance on EFX and increases its chances of success. These new candidates could address specific patient subpopulations or offer complementary mechanisms of action, further strengthening Akero's market position.
- Geographic Expansion: Akero can expand its clinical trials and eventual commercialization efforts into new geographic regions, particularly in Asia and Europe, where the prevalence of NASH is increasing. Entering these markets requires navigating regulatory hurdles and establishing local partnerships, but it offers significant growth potential. The global market for NASH treatments is expected to be substantial, making geographic expansion a key growth driver.
- Personalized Medicine Approach: Akero can explore the use of biomarkers and genetic testing to identify patients who are most likely to respond to EFX. This personalized medicine approach can improve treatment efficacy and reduce healthcare costs. By tailoring treatment to individual patient characteristics, Akero can differentiate itself from competitors and enhance its value proposition.
Opportunities
- Expansion into adjacent indications (e.g., type 2 diabetes).
- Strategic partnerships with larger pharmaceutical companies.
- Positive clinical trial results for EFX.
- Geographic expansion into new markets.
Threats
- Competition from other companies developing NASH treatments.
- Regulatory hurdles and delays.
- Clinical trial failures.
- Changes in reimbursement policies.
Competitive Advantages
- Proprietary efruxifermin (EFX) molecule with a unique mechanism of action.
- Strong intellectual property protection for EFX and related technologies.
- Clinical trial data demonstrating the efficacy and safety of EFX.
- Expertise in developing and commercializing therapies for cardio-metabolic diseases.
About AKRO
Akero Therapeutics, Inc., established in 2017 and headquartered in South San Francisco, California, is a clinical-stage biotechnology company dedicated to developing transformative medicines for cardio-metabolic diseases, with a primary focus on nonalcoholic steatohepatitis (NASH). Formerly known as Pippin Pharmaceuticals, Inc., the company rebranded to Akero Therapeutics in May 2018, signaling a renewed commitment to addressing metabolic dysfunction. Akero's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21 (FGF21), a naturally occurring hormone that plays a crucial role in regulating lipid, carbohydrate, and protein metabolism. EFX is designed to protect against cellular stress and restore metabolic balance throughout the body, offering a potential solution for the underlying causes of NASH. Currently, Akero is actively involved in clinical trials, including the Phase 2a BALANCED study, which evaluates the safety and efficacy of EFX in patients with biopsy-confirmed NASH. The company's strategic focus on NASH positions it within a high-growth market with significant unmet medical needs, making it an attractive player in the biotechnology landscape.
What They Do
- Develop medicines for cardio-metabolic diseases.
- Focus on treating nonalcoholic steatohepatitis (NASH).
- Develop efruxifermin (EFX), an analog of fibroblast growth factor 21.
- EFX protects against cellular stress.
- EFX regulates metabolism of lipids, carbohydrates, and proteins.
- Conduct Phase 2a clinical trials (BALANCED study) to evaluate EFX.
- Restore metabolic balance and improve overall health.
Business Model
- Develop and commercialize pharmaceutical products.
- Generate revenue through sales of approved therapies.
- Partner with larger pharmaceutical companies for co-development and commercialization.
- License intellectual property to generate revenue.
Industry Context
Akero Therapeutics operates within the biotechnology industry, specifically targeting the rapidly growing market for NASH treatments. NASH is a severe form of nonalcoholic fatty liver disease (NAFLD) affecting millions worldwide. The absence of approved therapies creates a significant unmet medical need, driving intense competition among biotech and pharmaceutical companies. The market for NASH treatments is projected to reach billions of dollars in the coming years, fueled by increasing prevalence of obesity and diabetes. Akero's focus on restoring metabolic balance with EFX positions it favorably against competitors developing treatments that address only specific aspects of the disease.
Key Customers
- Patients with nonalcoholic steatohepatitis (NASH).
- Healthcare providers who treat NASH patients.
- Pharmaceutical companies seeking to expand their portfolio of NASH treatments.
- Payers (insurance companies and government healthcare programs) who reimburse for NASH treatments.
Financials
Chart & Info
Akero Therapeutics, Inc. (AKRO) stock price: $54.65 (+0.00, +0.00%)
Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Oct 10, 2023
-
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
benzinga · Aug 28, 2023
-
Stocks That Hit 52-Week Lows On Monday
benzinga · Jun 13, 2022
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · Apr 21, 2022
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AKRO.
Price Targets
Wall Street price target analysis for AKRO.
MoonshotScore
What does this score mean?
The MoonshotScore rates AKRO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Akero Therapeutics, Inc. Healthcare Stock: Key Questions Answered
What does Akero Therapeutics, Inc. do?
Akero Therapeutics is a biotechnology company focused on developing medicines for nonalcoholic steatohepatitis (NASH) and other cardio-metabolic diseases. Their lead product candidate, efruxifermin (EFX), is designed to restore metabolic balance and improve overall health in NASH patients. EFX is an analog of fibroblast growth factor 21 (FGF21), a naturally occurring hormone that regulates lipid, carbohydrate, and protein metabolism. The company is currently conducting clinical trials to evaluate the safety and efficacy of EFX in NASH patients, positioning itself as a key player in the rapidly growing NASH treatment market.
Is AKRO stock worth researching?
AKRO stock presents a speculative but potentially rewarding investment opportunity. The company's focus on NASH, a market with significant unmet medical need, and its lead product candidate, EFX, offer substantial growth potential. However, as a clinical-stage biotech company, Akero carries inherent risks associated with drug development, including clinical trial failures and regulatory hurdles. The company's negative P/E ratio reflects its current lack of profitability. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in AKRO, weighing the potential upside against the risks.
What are the main risks for AKRO?
The main risks for Akero Therapeutics include the potential for clinical trial failures, regulatory setbacks, and competition from other companies developing NASH treatments. As a clinical-stage biotech company, Akero is heavily reliant on the success of its lead product candidate, EFX. Any negative data from clinical trials or delays in regulatory approval could significantly impact the company's stock price. Additionally, the NASH treatment market is becoming increasingly competitive, with several companies developing novel therapies. Akero also faces the risk of high cash burn and the need for additional financing, which could dilute existing shareholders.
What are the key factors to evaluate for AKRO?
Akero Therapeutics, Inc. (AKRO) currently holds an AI score of 46/100, indicating low score. Key strength: Novel mechanism of action of efruxifermin (EFX). Primary risk to monitor: Clinical trial failures or delays. This is not financial advice.
How frequently does AKRO data refresh on this page?
AKRO prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven AKRO's recent stock price performance?
Recent price movement in Akero Therapeutics, Inc. (AKRO) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Novel mechanism of action of efruxifermin (EFX). Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider AKRO overvalued or undervalued right now?
Determining whether Akero Therapeutics, Inc. (AKRO) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying AKRO?
Before investing in Akero Therapeutics, Inc. (AKRO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-02-03.
- Stock data pending update.